Cowen Starts Oyster Point Pharma (OYST) at Outperform, Street High $40 PT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Oyster Point Pharma Inc. (OYST) Reports Positive Top-Line Results from Phase 1 'ZEN' Study of Lead Nicotinic Agonist Nasal Spray
November 25, 2019 5:50 AM ESTOyster Point Pharma, Inc. (NASDAQ: OYST) announced the positive top-line results from its Phase 1 ZEN study in healthy volunteers. The ZEN Study was an open-label, single-center, randomized, 2-way crossover study to evaluate the relative bioavailability of varenicline administered as a preservative-free nasal spray (OC-01 nasal spray) as compared to varenicline administered orally as a single oral dose of Chantix®.
The ZEN study was designed to assess the relative bioavailability of varenicline administered intranasally at its highest intended clinical strength (1.2 mg/ml in a 50 microliter nasal spray) compared to varenicline... More
JPMorgan Starts Oyster Point Pharma (OYST) at Overweight
November 25, 2019 4:15 AM ESTJPMorgan analyst Oyster Point Pharma initiates coverage on Oyster Point Pharma (NASDAQ: OYST) with a Overweight rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Oyster Point Pharma... More
Piper Jaffray Starts Oyster Point Pharma (OYST) at Overweight
November 25, 2019 4:14 AM ESTPiper Jaffray analyst Tyler Van Buren initiates coverage on Oyster Point Pharma (NASDAQ: OYST) with a Overweight rating and a price target of $35.00.
For an analyst ratings summary and ratings history on Oyster Point Pharma... More

